Zim Laboratories Ltd

Zim Laboratories Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Zim Laboratories Ltd

₹ 73.2 -0.79%
31 Oct - close price
zimlab.in BSE: 541400 NSE: ZIMLAB
About

Incorporated in 1989, Zim Laboratories
Ltd manufactures formulation drugs and
pre formulation ingredients in India and
markets and sells these within and out
side India[1]

Key Points

Business Overview:[1]
ZLL is a EU-GMP, WHOGMP, NSF/ANSI 455-2 certified research-driven pharmaceutical company that develops, manufactures and supplies generic products in the oral solid dosage forms, both as pre-formulation intermediates ad finished formulations for certain key therapeutic segments. It offers both pharmaceutical and nutraceutical products.‍ Company has an in-house R&D capabilities to offer a range of non-infringing drug
delivery solutions based on process technologies

Website BSE NSE
  • Market Cap ₹ 357 Cr.
  • Current Price ₹ 73.2
  • High / Low ₹ 128 / 65.0
  • Stock P/E 38.4
  • Book Value ₹ 50.2
  • Dividend Yield 0.00 %
  • ROCE 8.21 %
  • ROE 4.93 %
  • Face Value ₹ 10.0
Edit ratios

Pros

Cons

  • Though the company is reporting repeated profits, it is not paying out dividend
  • The company has delivered a poor sales growth of 6.49% over past five years.
  • Promoter holding is low: 33.3%
  • Company has a low return on equity of 8.45% over last 3 years.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Edit Columns
Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025
92.50 99.26 100.32 104.45 67.01 85.26 95.82 117.39 82.00 89.72 95.40 108.52 71.43
81.12 87.14 87.68 89.40 62.47 76.29 84.64 101.96 74.12 81.32 83.63 93.28 67.10
Operating Profit 11.38 12.12 12.64 15.05 4.54 8.97 11.18 15.43 7.88 8.40 11.77 15.24 4.33
OPM % 12.30% 12.21% 12.60% 14.41% 6.78% 10.52% 11.67% 13.14% 9.61% 9.36% 12.34% 14.04% 6.06%
1.87 1.44 2.42 0.70 0.63 1.42 1.11 1.53 0.98 1.32 1.76 1.55 1.48
Interest 1.33 1.36 1.62 1.27 1.73 1.22 1.70 2.28 2.86 2.89 2.73 2.91 3.30
Depreciation 3.95 4.04 3.56 4.58 3.66 3.72 3.58 3.87 4.92 4.97 4.77 5.23 4.79
Profit before tax 7.97 8.16 9.88 9.90 -0.22 5.45 7.01 10.81 1.08 1.86 6.03 8.65 -2.28
Tax % 29.23% 30.64% 33.60% 27.88% -36.36% 23.30% 31.10% 26.92% 30.56% 34.41% 27.86% 37.34% -25.88%
5.64 5.66 6.57 7.14 -0.14 4.18 4.83 7.89 0.76 1.22 4.35 5.42 -1.69
EPS in Rs 1.16 1.16 1.35 1.47 -0.03 0.86 0.99 1.62 0.16 0.25 0.89 1.11 -0.35
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 TTM
266 268 235 272 332 274 304 329 397 365 376 365
278 238 203 238 289 255 267 292 345 325 332 325
Operating Profit -12 30 32 34 43 20 37 38 51 40 43 40
OPM % -4% 11% 14% 13% 13% 7% 12% 12% 13% 11% 12% 11%
2 -2 5 9 2 5 -3 5 6 5 6 6
Interest 10 14 10 9 11 13 11 8 6 7 11 12
Depreciation 7 9 9 10 11 13 15 15 16 15 20 20
Profit before tax -27 5 18 24 23 -1 9 19 36 23 18 14
Tax % -19% 5% -6% 24% 30% -216% 35% 33% 30% 27% 33%
-22 5 19 18 16 2 6 13 25 17 12 9
EPS in Rs 3.31 0.36 1.15 2.67 5.13 3.44 2.41 1.90
Dividend Payout % 0% 16% 4% 4% 5% 0% 0% 0% 0% 0% 0%
Compounded Sales Growth
10 Years: 4%
5 Years: 6%
3 Years: 4%
TTM: -4%
Compounded Profit Growth
10 Years: 10%
5 Years: 46%
3 Years: -3%
TTM: -47%
Stock Price CAGR
10 Years: %
5 Years: 19%
3 Years: -6%
1 Year: -32%
Return on Equity
10 Years: 9%
5 Years: 8%
3 Years: 8%
Last Year: 5%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Equity Capital 8 8 8 8 16 16 16 16 49 49 49
Reserves 86 91 110 128 135 136 141 154 145 183 196
93 96 81 81 77 90 82 53 62 112 118
78 61 60 80 96 81 81 112 79 99 102
Total Liabilities 265 256 259 297 325 323 320 335 335 443 464
87 92 89 94 101 111 103 103 107 160 164
CWIP 6 3 4 8 13 10 10 11 26 40 66
Investments 0 0 0 0 5 8 8 8 8 8 13
172 161 166 195 206 194 199 213 193 234 222
Total Assets 265 256 259 297 325 323 320 335 335 443 464

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
22 32 37 37 21 32 47 35 11 51
-12 -7 -26 -23 -19 -6 -14 -35 -72 -41
-10 -25 -10 -15 -2 -26 -33 1 60 -9
Net Cash Flow -0 -0 1 -1 0 0 -0 1 -1 0

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Debtor Days 111 120 137 119 99 84 77 90 81 100 91
Inventory Days 104 88 108 134 126 144 125 171 99 173 188
Days Payable 144 109 137 172 165 168 150 186 109 133 156
Cash Conversion Cycle 71 99 108 81 61 60 52 75 71 140 123
Working Capital Days 38 35 55 37 41 40 41 59 61 55 48
ROCE % 13% 14% 13% 15% 5% 10% 12% 17% 10% 8%

Shareholding Pattern

Numbers in percentages

4 Recently
Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025
33.26% 33.26% 33.26% 33.26% 33.26% 33.26% 33.26% 33.26% 33.26% 33.26% 33.26% 33.26%
0.00% 0.00% 0.06% 0.00% 0.00% 0.01% 0.00% 0.00% 0.21% 0.01% 0.03% 0.00%
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.24% 0.24% 0.24% 0.24%
66.73% 66.74% 66.69% 66.75% 66.74% 66.74% 66.74% 66.73% 66.29% 66.49% 66.46% 66.52%
No. of Shareholders 6,0275,8798,98215,30517,34217,10017,48317,71617,45017,44816,64117,282

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Credit ratings

Concalls